#Leniolisib, a PI3Kδ inhibitor, improves the pathophysiology of APDS. In @jhumimmunity.org, Rao, Uzel @charlesuni.cuni.cz et al. demonstrate the safety and efficacy of leniolisib in patients with APDS ≥12 years of age receiving up to 7 years of treatment. rupress.org/jhi/article/...

#Leniolisib, a PI3Kδ inhibitor, improves the pathophysiology of APDS. Rao, Uzel @charlesuni.cuni.cz et al. demonstrate the safety and efficacy of leniolisib in patients with APDS ≥12 years of age receiving up to 7 years of treatment. rupress.org/jhi/article/...

#InbornErrorsOfImmunity